Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC NWfHenFWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYfvTpR[cW6qaXLpeJMhfGinIG\FS2YucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJGhWXkWFcx?= MorxNVg3OjB|OEK=
HUVEC MWDLbY5ie2ViYYPzZZk> MXfpcohq[mm2czDWSWdHNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKF[HR1\SMVIhcW5iSGXWSWMh[2WubIOge4l1cCCjbjDJR|UxKG:oIPMIwFghdk1? M3fudFE5PjJyM{iy
MM M1O2UmtqdmG|ZTDhd5NigQ>? MYrpcohq[mm2czDWSWdHNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKG[udEG= M4fz[|E4OTZ2M{Oy
MM.1S NVzRWGVST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYrmN4tSOTBizsznM41N MVzpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MUSxO|E3PDN|Mh?=
MM.1R NYXKUGVJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXGxNEDPxGdxbVy= NFPXVG9qdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= NUn0N45vOTdzNkSzN|I>
RPMI MlfnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mkm3NVAh|rypL33M M{fJdolvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq M3jJU|E4OTZ2M{Oy
Dox40 MljDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYHlPIdCOTBizsznM41N M3i3dolvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq M1HiXFE4OTZ2M{Oy
INA-6 NGnSflhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX:xNEDPxGdxbVy= MVrpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MmfpNVcyPjR|M{K=
OPM2 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWmxNEDPxGdxbVy= NWPi[pZscW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= Mn7iNVcyPjR|M{K=
U266 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFjsUHkyOCEQvHevcWw> NI\XdYZqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= NInZS5EyPzF4NEOzNi=>
MM.1S NGO2R|hkgXSxdH;4bYNqfHliYYPzZZk> M2DGd|IxKM7:Zz;tUC=> Mn\nbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= NVPycm9zOTdzNkSzN|I>
MM.1R NVyy[oJk[3m2b4TvfIlkcXS7IHHzd4F6 MkDnNlAh|rypL33M M1PpSYlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NEHISYgyPzF4NEOzNi=>
RPMI NX\VZ4hF[3m2b4TvfIlkcXS7IHHzd4F6 NH\RRpczOCEQvHevcWw> M1yzWYlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= Mnm3NVcyPjR|M{K=
Dox40 MXLjfZRwfG:6aXPpeJkh[XO|YYm= MoXwNlAh|rypL33M MVHpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NYjnZ2UxOTdzNkSzN|I>
INA-6 NGrwdHFkgXSxdH;4bYNqfHliYYPzZZk> MW[yNEDPxGdxbVy= MYHpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NVHPT2NZOTdzNkSzN|I>
OPM2 MXTjfZRwfG:6aXPpeJkh[XO|YYm= MVmyNEDPxGdxbVy= M4fvSIlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= M{j1XVE4OTZ2M{Oy
U266 M3rZXYN6fG:2b4jpZ4l1gSCjc4PhfS=> NV\ic3Y1OjBizsznM41N M{fOXolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NX76OIUzOTdzNkSzN|I>
MM.1S MoHySpVv[3Srb36gZZN{[Xl? Mkj5d5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w MV[xO|E3PDN|Mh?=
MM.1R MXnGeY5kfGmxbjDhd5NigQ>? NXvZXllCe3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u NXeydGU1OTdzNkSzN|I>
Dox40 NVz1S3VrTnWwY4Tpc44h[XO|YYm= NGXXSGp{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= MonlNVcyPjR|M{K=
OPM2 M4r5[mZ2dmO2aX;uJIF{e2G7 M4PkbpN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= M4SxXFE4OTZ2M{Oy
HBMEC M33sbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2jDc54yOCEQvF2= MUDEUXNQ M3r4U2lEPTB;MTFOwG0> M1rGSVIyODhzNkW2
HBMEC MYTGeY5kfGmxbjDhd5NigQ>? MmPtglEh|ryP MUDEUXNQ NXnYUINX[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= M1fVbVIyODhzNkW2
HBMEC MnLSSpVv[3Srb36gZZN{[Xl? M{D5[54yKM7:TR?= NUXiOpFTTE2VTx?= M3jYdIRqe3K3cITzJJRp\SCUYYOtVoFnNUWUSzDwZZRpf2G7IITodo92\2hiZHXjdoVie2WmIIDoc5NxcG:{eXzheIVlKE2HS{GvNkBidmRiRWLLNU8z Ml7yNlExQDF4NU[=
HBMEC NH7Be3JHfW6ldHnvckBie3OjeR?= MX7+NlAh|ryP NEfzem9FVVOR Mlr5[Il{enWydIOgOVAmKG:oIIT1ZoUh\m:{bXH0bY9vKGG2IEGg{txO M1LLNVIyODhzNkW2
MDA-MB-231 MontS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{\Xdp4yOCEQvF2= MmnySG1UVw>? MVnJR|UxRTVizszN M3;pOVIyODhzNkW2
MDA-MB-231 MXzGeY5kfGmxbjDhd5NigQ>? MWKwMlUh|ryP MYfEUXNQ NFPhOXhqdmirYnn0d{B1cGViRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6 M3jtcVIyODhzNkW2
MDA-MB-231 MVzGeY5kfGmxbjDhd5NigQ>? NIOzW2E2KM7:TR?= M2\iRmROW09? NED5c4xqdmS3Y3XzJIEh[2WubD3jfYNt\SCjcoLld5Q> NGruZ5kzOTB6MU[1Oi=>
J82 MUfjfZRwfG:6aXPpeJkh[XO|YYm= MoC1glExKM7:TR?= NX6zcFZYTE2VTx?= M{joXmlEPTB;MkSuOVch|ryP M13QN|IyPTJ7OUCw
T24 M1\FZoN6fG:2b4jpZ4l1gSCjc4PhfS=> MVX+NVAh|ryP MXvEUXNQ NVjN[HdvUUN3ME21Nk41PSEQvF2= MUmyNVUzQTlyMB?=
HT1376 NGnDc2dkgXSxdH;4bYNqfHliYYPzZZk> M3fjXJ4yOCEQvF2= NFjrU|JFVVOR NFXuRYlKSzVyPUK4MlIyKM7:TR?= NWjDVpBLOjF3Mkm5NFA>
RT4 MVjjfZRwfG:6aXPpeJkh[XO|YYm= M{ToZ54yOCEQvF2= MlrSSG1UVw>? MYXJR|UxRTVwMUSg{txO M1OzW|IyPTJ7OUCw
CRL1749 M3S2bIN6fG:2b4jpZ4l1gSCjc4PhfS=> MXv+NVAh|ryP MVjEUXNQ M4r6emlEPTB;MkKuOlkh|ryP MWiyNVUzQTlyMB?=
HTB9 NE\aNI5kgXSxdH;4bYNqfHliYYPzZZk> MkHXglExKM7:TR?= M{TKR2ROW09? MUDJR|UxRTFzLki0JO69VQ>? NX2xNXZOOjF3Mkm5NFA>
Sup Mn;vZ5l1d3SxeHnjbZR6KGG|c3H5 NX\oc2pThjFyIN88US=> NECzdW5FVVOR NGC1SVBKSzVyPUWzMlMzKM7:TR?= MlLINlE2Ojl7MEC=
HTB3 MYfjfZRwfG:6aXPpeJkh[XO|YYm= M3rGSZ4yOCEQvF2= M4nEfGROW09? NY\zbHZiUUN3ME2xOE4yPiEQvF2= MkfWNlE2Ojl7MEC=
CEC M1LIRWZ2dmO2aX;uJIF{e2G7 NFG2[Ip,OTBizsznM41N M3TkRmROW09? NXzoOHBw\G:5bj3y[Yd2dGG2ZYOgWmVITiCuZY\lcJM> MVeyNVYzODh{Mh?=
RPE MojzSpVv[3Srb36gZZN{[Xl? NVvRd49XhjFyIN88[{9uVA>? Mlm0SG1UVw>? MWXkc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= Ml;nNlE3OjB6MkK=
CEC NHrH[llHfW6ldHnvckBie3OjeR?= MVj+OUDPxGdxbVy= M2PUTWROW09? NYHGXIli[myxY3vzJIVv\G:2aHXsbYFtKGOnbHygcYloemG2aX;u NXPEbFZROjF4MkC4NlI>
5637 MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1fJPWROW09? Moq1TWM2OD1zNT6w5qCK|ryP M3T4SFI{QDh5NkC1
J82 MkPyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2jHV2ROW09? MmL4TWM2OD1zOD605qCK|ryP NXnBNFRsOjN6OEe2NFU>
5637 M1jUcGF2fG:yaHHnfUBie3OjeR?= MoOwNlAh|ryP MWnEUXNQ M3vSXpRzcWepZYLzJJRp\SCjdYTvdIhi\2mlIIDyc4Nme3N? NGXLXWQzOzh6N{[wOS=>
J82 NXfsOlQ4SXW2b4DoZYd6KGG|c3H5 M17CXVIxKM7:TR?= NWTGPYJYTE2VTx?= MlzreJJq\2encoOgeIhmKGG3dH;wbIFocWNicILvZ4V{ew>? Mmr4NlM5QDd4MEW=
5637 MXLGeY5kfGmxbjDhd5NigQ>? NV;ZWWg{OjBizszN M{XRVGROW09? M1fYbolv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> MlHXNlM5QDd4MEW=
J82 NVzFR4hrTnWwY4Tpc44h[XO|YYm= MVKyNEDPxE1? MlPBSG1UVw>? NI\VfoxqdmS3Y3XzJIx6e2:|b33hcE1l\XCnbnTlcpQhdmWlcn;zbZM> NV\OU3lLOjN6OEe2NFU>
5637 M2XFNGZ2dmO2aX;uJIF{e2G7 NWLVWmlVOjBizszN M2P3OmROW09? NIfJTHJqdmS3Y3XzJIx6e2:|b33lJIFtfGW{YYTpc44h[W6mIHnubIljcXS|IFPCJIFkfGm4aYT5 M1q3fVI{QDh5NkC1
J82 M{XYN2Z2dmO2aX;uJIF{e2G7 NHLRZ2IzOCEQvF2= NEXMZ4tFVVOR MlKzbY5lfWOnczDsfZNwe2:vZTDhcJRmemG2aX;uJIFv\CCrbnjpZol1eyCFQjDhZ5Rqfmm2eR?= MVOyN|g5PzZyNR?=
KATO-II NIKwVZlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1;ZT|Uh|ryP NWTZXVJUTE2VTx?= NXy0Rnlq[myxY3vzJJBzd2yrZnXyZZRqd25? Mn35NlUzPDl3NUe=
OCUM-2M MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1XETlUh|ryP M37XZWROW09? M2C4V4Jtd2OtczDwdo9tcW[ncnH0bY9v NUm0PWxDOjV{NEm1OVc>
SNU-16 NUPq[JFxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4DtSFUh|ryP M3TLNGROW09? MoSzZoxw[2u|IIDyc4xq\mW{YYTpc44> MlyzNlUzPDl3NUe=
HSC-39 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXq1JO69VQ>? M2LUc2ROW09? M3iyOIJtd2OtczDwdo9tcW[ncnH0bY9v MW[yOVI1QTV3Nx?=
KATO-II M1LzXIN6fG:2b4jpZ4l1gSCjc4PhfS=> MoLOglExKM7:TR?= MX;EUXNQ NX3W[JZDUUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= M3XXfVI2OjR7NUW3
OCUM-2M NILsb2VkgXSxdH;4bYNqfHliYYPzZZk> M{K3U54yOCEQvF2= M2n3SmROW09? M4PTPGlEPTB;MD6xJJRwKDJwMDFOwI1wdC:O NF2zdXMzPTJ2OUW1Oy=>
SNU-16 MlnkZ5l1d3SxeHnjbZR6KGG|c3H5 M{Dpbp4yOCEQvF2= MkPJSG1UVw>? Ml20TWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? MXGyOVI1QTV3Nx?=
HSC-39 NXzyNJhP[3m2b4TvfIlkcXS7IHHzd4F6 M2K4dp4yOCEQvF2= M{fZZWROW09? NUDOcVFCUUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= MXyyOVI1QTV3Nx?=
NIH 3T3 NHLtcoxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYnONnJnhjFyIN88US=> MWfEUXNQ NIHJOJhqdmirYnn0d{Bk\WyuIHfyc5d1cCCjbnSgZ49td267IH\vdo1ifGmxbh?= M1rmPFI2OjR7NUW3
KATO-III NInGc5BHfW6ldHnvckBie3OjeR?= NFn0VG4yKM7:TR?= MlS0SG1UVw>? MnnabY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= M{nOUlI2OjR7NUW3
OCUM-2M MV\GeY5kfGmxbjDhd5NigQ>? M4rDNFEh|ryP MX\EUXNQ M1XzWYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NH;IT4gzPTJ2OUW1Oy=>
KATO-III NY\EVIt5SXCxcITvd4l{KGG|c3H5 NGK1fGgyKM7:TR?= NIDaUlhFVVOR MWHpcoR2[2W|IHHwc5B1d3Orcx?= NF7QR5kzPTJ2OUW1Oy=>
OCUM-2M NGi4dFdCeG:ydH;zbZMh[XO|YYm= NEXCWYIyKM7:TR?= NVLJPVVPTE2VTx?= M2\FdIlv\HWlZYOgZZBweHSxc3nz MljKNlUzPDl3NUe=
KATO-III MY\GeY5kfGmxbjDhd5NigQ>? MV2xJO69VQ>? NIDweXdFVVOR MV;pcohq[mm2czDGS2ZTOiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nJI1wdGWldXzldy=> MmXONlUzPDl3NUe=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID